日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG

以 CpG-1826 和四种浓度的 Montanide-ISA-720-VG 为佐剂的 C. muridarum 疫苗的安全性和有效性

Anatoli Slepenkin, Sukumar Pal, Amy Rasley, Matthew A Coleman, Luis M de la Maza

CT584 Is Not a Protective Vaccine Antigen against Respiratory Chlamydial Challenge in Mice

CT584 不是针对小鼠呼吸道衣原体的保护性疫苗抗原

Steven Hoang-Phou, Sukumar Pal, Anatoli Slepenkin, Abisola Abisoye-Ogunniyun, Yuliang Zhang, Sean F Gilmore, Megan L Shelby, Feliza A Bourguet, Mariam V Mohagheghi, Aleksandr Noy, Amy Rasley, Luis M de la Maza, Matthew A Coleman

Evaluation in mice of cell-free produced CT584 as a Chlamydia vaccine antigen

在小鼠中评估无细胞产生的 CT584 作为衣原体疫苗抗原的效果

Steven Hoang-Phou, Sukumar Pal, Anatoli Slepenkin, Abisola Abisoye-Ogunniyun, Yuliang Zhang, Sean F Gilmore, Megan Shelby, Feliza Bourguet, Mariam Mohagheghi, Aleksandr Noy, Amy Rasley, Luis M de la Maza, Matthew A Coleman

A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens

通过使用生物素化抗原修饰细菌外膜囊泡实现的模块化疫苗平台

Kevin B Weyant, Ayomide Oloyede, Sukumar Pal, Julie Liao, Mariela Rivera-De Jesus, Thapakorn Jaroentomeechai, Tyler D Moeller, Steven Hoang-Phou, Sean F Gilmore, Riya Singh, Daniel C Pan, David Putnam, Christopher Locher, Luis M de la Maza, Matthew A Coleman, Matthew P DeLisa

Determination of the safety and efficacy of recombinant Chlamydia muridarum MOMP vaccines, formulated with CpG-1826 and 70%, 50%, 30% or 10% concentrations of Montanide ISA-720 VG, to elicit protective immune responses against a C. muridarum respiratory challenge

确定重组沙眼衣原体 MOMP 疫苗的安全性和有效性,该疫苗由 CpG-1826 和 70%、50%、30% 或 10% 浓度的 Montanide ISA-720 VG 配制而成,可引发针对沙眼衣原体呼吸道攻击的保护性免疫反应

Luis de la Maza, Anatoli Slepenkin, Sukumar Pal, Amy Rasley, Matthew Coleman

Induction of Protection in Mice against a Chlamydia muridarum Respiratory Challenge by a Vaccine Formulated with the Major Outer Membrane Protein in Nanolipoprotein Particles

用纳米脂蛋白颗粒中的主要外膜蛋白配制的疫苗诱导小鼠对沙眼衣原体呼吸道攻击的保护

Delia F Tifrea, Wei He, Sukumar Pal, Angela C Evans, Sean F Gilmore, Nicholas O Fischer, Amy Rasley, Matthew A Coleman, Luis M de la Maza

Induction of protection in mice against a respiratory challenge by a vaccine formulated with exosomes isolated from Chlamydia muridarum infected cells

使用从感染沙眼衣原体的细胞中分离出的外泌体配制的疫苗,在小鼠体内诱导对呼吸道感染的保护作用

Sukumar Pal, Yeva Mirzakhanyan, Paul Gershon, Delia F Tifrea, Luis M de la Maza

Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold

使用乳酸奈瑟菌孔蛋白 B 作为支架,通过与鼠衣原体主要外膜蛋白可变结构域配制的嵌合疫苗来预防衣原体呼吸道感染

Delia F Tifrea, Sukumar Pal, Jeff Fairman, Paola Massari, Luis M de la Maza

Computational modeling of TC0583 as a putative component of the Chlamydia muridarum V-type ATP synthase complex and assessment of its protective capabilities as a vaccine antigen

TC0583 作为 Chlamydia muridarum V 型 ATP 合酶复合物的假定成分的计算建模及其作为疫苗抗原的保护能力评估

Delia F Tifrea, Michael L Barta, Sukumar Pal, P Scott Hefty, Luis M de la Maza

TRAIL-R1 is a negative regulator of pro-inflammatory responses and modulates long-term sequelae resulting from Chlamydia trachomatis infections in humans

TRAIL-R1 是促炎反应的负调节剂,可调节人类沙眼衣原体感染引起的长期后遗症

Mufadhal Al-Kuhlani, James Rothschild, Sukumar Pal, Luis M de la Maza, Sander Ouburg, Servaas A Morré, Deborah Dean, David M Ojcius